TRAF3 Antibody

What is TRAF3 and what are its primary functions in cellular signaling?

TRAF3 (TNF receptor-associated factor 3) is a cytoplasmic E3 ubiquitin ligase that regulates various signaling pathways, including NF-kappa-B, mitogen-activated protein kinase (MAPK), and interferon regulatory factor (IRF) pathways. This multifunctional protein controls numerous biological processes in both immune and non-immune cell types. In TLR and RLR signaling pathways, TRAF3 promotes the synthesis of 'Lys-63'-linked polyubiquitin chains on several substrates such as ASC, leading to activation of type I interferon responses or inflammasome formation .

TRAF3 also functions as a negative regulator in the NF-kappa-B pathway, particularly following activation of certain Toll-like receptors (TLRs) such as TLR4. This negative regulation may prevent uncontrolled inflammatory responses. Additionally, TRAF3 serves as a constitutive negative regulator of the alternative NF-kappa-B pathway, which controls B-cell survival and lymphoid organ development .

How does TRAF3 specifically function in T lymphocytes?

In T lymphocytes, TRAF3 regulates multiple signaling pathways critical for proper T cell development, activation, and function. It modulates signals through the T cell receptor (TCR), costimulatory receptors, and multiple cytokine receptors . Studies using TRAF3-deficient mice have shown that TRAF3 is essential for robust T cell-mediated immune responses to immunization and infection.

Specifically, TRAF3 affects TCR signal transduction through interactions with the TCR complex components. Upon TCR ligation, a signaling cascade is initiated involving CD3 subunits, LCK, ZAP70, and the LAT signalosome. TRAF3 influences these early signaling events, as T cells lacking TRAF3 display altered activation in response to TCR stimulation . TRAF3 also plays a critical role in regulating IL-2 receptor signaling by recruiting PTPN2/TCPTP to the IL-2R complex, where it dephosphorylates JAKs to modulate signaling strength .

How does TRAF3 deficiency affect T cell function and development?

TRAF3 deficiency significantly alters T cell function and development in several key ways:

• TRAF3-deficient CD4+ T cells show impaired response to CD3/TCR and CD28 stimulation, with reduced upregulation of early activation markers CD25 and CD69, decreased proliferation, and compromised survival compared to wild-type T cells .

• Cytokine production is altered in TRAF3-deficient T cells. After TCR/CD28 stimulation, TRAF3-/- CD4+ T cells produce lower levels of IL-2, IL-4, IL-17, and IFNγ compared to control cells .

• Mice lacking TRAF3 in T cells (T-Traf3-/-) have a 2-3 fold greater frequency of Foxp3+ regulatory T cells (Tregs), resulting from enhanced differentiation of Treg precursors to mature Treg cells .

• TRAF3-deficient T cells show increased expression of glucocorticoid-induced TNFR-related protein (GITR) both before and after CD3+CD28 stimulation, which is not solely attributable to the expanded Treg population .

What factors should be considered when selecting a TRAF3 antibody for specific experimental applications?

When selecting a TRAF3 antibody for research, several critical factors should be evaluated to ensure experimental success:

• Antibody Type: Consider whether a polyclonal or monoclonal antibody is most appropriate for your application. Polyclonal antibodies like ab217033 recognize multiple epitopes and may provide stronger signals in certain applications but with potentially lower specificity. Monoclonal antibodies like ab239357 recognize single epitopes, offering higher specificity but potentially lower signal intensity .

• Validated Applications: Choose an antibody validated for your specific application. For example, ab217033 is suitable for immunohistochemistry on paraffin-embedded tissues (IHC-P) and intracellular flow cytometry, while ab239357 is validated for Western blotting .

• Species Reactivity: Ensure the antibody recognizes TRAF3 in your experimental species. Available antibodies react with human, mouse, and rat TRAF3, but cross-reactivity varies between products .

• Epitope Location: Consider the epitope location relative to your research question. For instance, ab217033 targets a synthetic peptide within human TRAF3 amino acids 100-200, which may be important if studying specific domains or if post-translational modifications might mask certain epitopes .

• Citation Record: Review publications that have used the antibody successfully in applications similar to yours. Antibodies with multiple citations generally have more reliable performance data .

How should TRAF3 antibodies be validated before use in critical experiments?

Thorough validation of TRAF3 antibodies is essential before conducting critical experiments. A comprehensive validation approach should include:

• Positive and Negative Controls: Use tissues or cell lines known to express or lack TRAF3. For example, Jurkat cells express TRAF3 and can serve as a positive control for flow cytometry . For negative controls, consider using TRAF3 knockout cells or TRAF3-deficient cell lines where available.

• Multiple Detection Methods: Validate antibody specificity using at least two independent detection methods (e.g., Western blot and immunohistochemistry) to confirm consistent results across platforms.

• Antibody Titration: Perform a titration series to determine the optimal antibody concentration that provides maximum specific signal with minimal background. For instance, ab217033 has been effectively used at 1/200 dilution for IHC-P applications and 0.2μg concentration for flow cytometry .

• Knockdown/Knockout Validation: The gold standard for antibody validation is testing in samples where the target protein has been depleted through genetic approaches (CRISPR/Cas9, siRNA) to confirm signal loss.

• Peptide Competition Assay: Pre-incubate the antibody with the immunizing peptide (if available) to block specific binding and confirm that the observed signal is specific to TRAF3.

What are the optimal conditions for using TRAF3 antibodies in Western blot analysis?

For optimal Western blot detection of TRAF3 using antibodies such as ab239357, the following protocol parameters should be considered:

• Sample Preparation:

  • Lyse cells in a buffer containing protease inhibitors to prevent TRAF3 degradation

  • Include phosphatase inhibitors if studying phosphorylation status

  • Denature samples at 95°C for 5 minutes in reducing SDS sample buffer

• Gel Electrophoresis:

  • Use 8-10% SDS-PAGE gels as TRAF3 has a molecular weight of approximately 62-64 kDa

  • Load 20-30 μg of total protein per lane for cell lysates

• Transfer Conditions:

  • Transfer to PVDF or nitrocellulose membrane at 100V for 1 hour or 30V overnight

  • Confirm transfer efficiency with reversible protein staining

• Blocking and Antibody Incubation:

  • Block membrane in 5% non-fat dry milk or 5% BSA in TBST for 1 hour at room temperature

  • Incubate with primary TRAF3 antibody (e.g., ab239357) at manufacturer's recommended dilution (typically 1:1000 to 1:2000) overnight at 4°C

  • Wash thoroughly with TBST (at least 3 x 10 minutes)

  • Incubate with appropriate HRP-conjugated secondary antibody for 1 hour at room temperature

• Detection:

  • Develop using ECL substrate

  • Expected band size for TRAF3 is approximately 62-64 kDa

• Controls:

  • Include positive control samples known to express TRAF3

  • Consider using TRAF3-deficient samples as negative controls where available

How can researchers effectively study TRAF3 interactions with TCR signaling components?

Investigating TRAF3 interactions with TCR signaling components requires sophisticated experimental approaches:

• Co-immunoprecipitation (Co-IP) Studies:

  • Immunoprecipitate TRAF3 using validated antibodies and analyze co-precipitated TCR signaling components

  • Alternatively, immunoprecipitate TCR complex components and detect TRAF3 in the precipitates

  • Include appropriate controls (IgG control, lysates from TRAF3-deficient cells)

  • Consider conducting experiments under both basal and TCR-stimulated conditions to capture dynamic interactions

• Proximity Ligation Assay (PLA):

  • Use this technique to visualize protein-protein interactions in situ

  • Combine TRAF3 antibodies with antibodies against TCR signaling components (CD3, ZAP70, LAT)

  • This approach can reveal spatial and temporal aspects of interactions following TCR stimulation

• CRISPR/Cas9-mediated Gene Editing:

  • Generate TRAF3-deficient T cell lines using CRISPR/Cas9 technology

  • Compare TCR signaling events between wild-type and TRAF3-deficient cells

  • Reconstitute with wild-type or mutant TRAF3 to identify functional domains required for TCR signal regulation

• Phospho-flow Cytometry:

  • Analyze phosphorylation of downstream TCR signaling molecules (ZAP70, LAT, PLCγ1) in TRAF3-sufficient versus TRAF3-deficient T cells

  • This approach enables single-cell resolution analysis of signaling pathway activation

• Live Cell Imaging:

  • Use fluorescently-tagged TRAF3 and TCR components to track their interactions in real-time

  • This technique can reveal the dynamics of TRAF3 recruitment to the immunological synapse during T cell activation

What approaches can be used to study TRAF3's role in cytokine receptor signaling in T cells?

TRAF3 plays significant roles in regulating cytokine receptor signaling in T cells, particularly for IL-2 and interferons. To study these functions, researchers can employ these approaches:

• JAK-STAT Signaling Analysis:

  • Measure phosphorylation of JAK kinases and STAT transcription factors downstream of cytokine receptors in TRAF3-sufficient and TRAF3-deficient T cells

  • Techniques include Western blotting, phospho-flow cytometry, and immunofluorescence microscopy

  • Focus on STAT5 phosphorylation for IL-2 signaling and STAT1/STAT2 for interferon signaling

• Protein-Protein Interaction Studies:

  • Investigate TRAF3 interactions with cytokine receptor components and signaling intermediates

  • Research indicates TRAF3 recruits PTPN2/TCPTP to the IL-2R complex to regulate signaling; similar approaches can study other cytokine receptors

  • Use co-immunoprecipitation, proximity ligation assays, or FRET-based approaches

• Cytokine-Induced Gene Expression:

  • Perform RNA-seq or qRT-PCR to analyze cytokine-induced gene expression profiles in TRAF3-sufficient versus TRAF3-deficient T cells

  • Chromatin immunoprecipitation (ChIP) can be used to assess STAT binding to target gene promoters, such as the high-affinity IL-2Rα chain

• Functional Readouts:

  • Measure T cell proliferation, differentiation, and cytokine production in response to specific cytokine stimulation

  • Compare these outcomes between TRAF3-sufficient and TRAF3-deficient T cells

  • Include both direct cytokine stimulation and TCR+cytokine combined stimulation conditions

• Domain Mapping:

  • Generate TRAF3 mutants lacking specific domains and assess their ability to regulate cytokine receptor signaling

  • This approach can identify critical regions required for interaction with phosphatases or other regulatory proteins

How can researchers effectively investigate TRAF3's E3 ubiquitin ligase activity in T cell signaling pathways?

TRAF3 functions as an E3 ubiquitin ligase, and this activity is critical for its regulatory roles in T cell signaling. To investigate this aspect of TRAF3 function:

• Ubiquitination Assays:

  • Immunoprecipitate potential TRAF3 substrates and blot for ubiquitin to detect ubiquitination

  • Use antibodies specific for different ubiquitin linkages (K48, K63, K33) to determine the type of ubiquitination

  • Compare ubiquitination patterns between wild-type and TRAF3-deficient T cells

  • For in vitro studies, recombinant TRAF3, E1, E2 enzymes, ubiquitin, and substrate proteins can be used to reconstitute the ubiquitination reaction

• RING Domain Mutant Studies:

  • Generate TRAF3 constructs with mutations in the RING domain that disrupt E3 ligase activity

  • Express these mutants in TRAF3-deficient T cells and assess their ability to restore normal signaling

  • Compare with wild-type TRAF3 reconstitution to determine the importance of E3 ligase activity

• Mass Spectrometry:

  • Use immunoprecipitation followed by mass spectrometry to identify ubiquitinated substrates of TRAF3

  • Employ SILAC (Stable Isotope Labeling by Amino acids in Cell culture) or TMT (Tandem Mass Tag) approaches to quantitatively compare ubiquitination in TRAF3-sufficient versus TRAF3-deficient T cells

• Proteasome Inhibition Studies:

  • Treat cells with proteasome inhibitors to determine if TRAF3-mediated ubiquitination leads to proteasomal degradation

  • This is particularly relevant for studying TRAF3's role in negative regulation of alternative NF-kappa-B pathway components like MAP3K14

• Linkage-Specific Ubiquitin Chain Analysis:

  • TRAF3 promotes different types of ubiquitin linkages in different contexts

  • Use linkage-specific antibodies or mass spectrometry techniques to distinguish between K48 (degradative), K63 (signaling), and K33 linkages

  • Research indicates TRAF3 promotes K63-linked chains for type I interferon response activation and K33-linked chains when TLR4 orchestrates bacterial expulsion

Why might researchers observe discrepancies in TRAF3 detection between different experimental systems?

Researchers may encounter discrepancies in TRAF3 detection across different experimental systems due to several factors:

• Expression Level Variations:

  • TRAF3 expression levels vary naturally between different cell types and tissues

  • Expression may be altered by activation status, particularly in immune cells

  • Some cell lines may have mutations or alterations in TRAF3 expression

• Antibody-Specific Factors:

  • Different antibodies recognize distinct epitopes that may be differentially accessible

  • Post-translational modifications may mask epitopes in certain contexts

  • Antibody clone ab217033 targets amino acids 100-200 of human TRAF3, while other antibodies may target different regions

  • Fixation and permeabilization methods can affect epitope accessibility differently across techniques

• Alternative Splicing:

  • TRAF3 can undergo alternative splicing, producing protein variants that may not be recognized by all antibodies

  • These variants may have different functional properties and expression patterns

• Technical Considerations:

  • Sample preparation methods (denaturing vs. native conditions) can affect epitope exposure

  • Detection sensitivity varies between methods (Western blot vs. flow cytometry vs. IHC)

  • Signal amplification steps differ between techniques

• Biological Context:

  • Protein-protein interactions may mask TRAF3 epitopes in specific signaling complexes

  • Subcellular localization changes upon activation may affect detection in certain compartments

When encountering such discrepancies, it is advisable to:

• Validate findings using multiple antibodies targeting different epitopes

• Employ multiple detection techniques

• Include appropriate positive and negative controls

• Consider using genetic approaches (siRNA knockdown or CRISPR/Cas9 knockout) to confirm specificity

How can researchers distinguish between TRAF3's roles in different signaling pathways within T cells?

Distinguishing between TRAF3's roles in multiple signaling pathways within T cells requires sophisticated experimental approaches:

• Pathway-Specific Stimulation:

  • Selectively activate specific pathways using defined stimuli:

    • Anti-CD3/CD28 antibodies for TCR signaling

    • Recombinant cytokines for cytokine receptor signaling

    • TLR ligands for innate immune receptor signaling

  • Compare responses between TRAF3-sufficient and TRAF3-deficient T cells for each pathway

• Genetic Rescue Experiments with Domain Mutants:

  • Generate a panel of TRAF3 constructs with mutations in specific functional domains

  • Express these mutants in TRAF3-deficient T cells

  • Assess which mutants rescue which signaling pathways to map domain-specific functions

• Biochemical Isolation of Signaling Complexes:

  • Immunoprecipitate components of specific signaling pathways (e.g., TCR complex, IL-2R, IFNGR)

  • Analyze TRAF3 association with these complexes under different stimulation conditions

  • Use proximity ligation assays to visualize these interactions in intact cells

• Temporal Analysis of Signaling Events:

  • Examine the kinetics of TRAF3 involvement in different pathways

  • Time-course experiments can reveal when TRAF3 engages with each pathway

  • This approach can distinguish between primary and secondary effects

• Combinatorial Pathway Inhibition:

  • Use specific inhibitors of signaling components (e.g., JAK inhibitors, TCR signaling inhibitors)

  • Determine how these inhibitors affect TRAF3-dependent outcomes

  • This approach can help delineate pathway crosstalk versus direct TRAF3 effects

What are the recommended approaches for studying TRAF3's role in regulatory T cell development and function?

Research indicates that TRAF3 influences regulatory T cell (Treg) development and function, with TRAF3-deficient mice showing increased Treg frequency. To study this aspect of TRAF3 biology:

• Treg Differentiation Assays:

  • Compare in vitro differentiation of naïve CD4+ T cells into Tregs between TRAF3-sufficient and TRAF3-deficient cells

  • Use varying concentrations of TGF-β and IL-2 to assess sensitivity to Treg-inducing signals

  • Quantify Foxp3 induction and other Treg markers (CD25, CTLA-4, GITR)

  • As reported, T-Traf3-/- mice have 2-3 fold greater frequency of Foxp3+ Tregs due to enhanced differentiation of Treg precursors

• Thymic Development Studies:

  • Analyze thymic development of Tregs in conditional TRAF3 knockout mice (T-Traf3-/-)

  • Examine different developmental stages using flow cytometry

  • Assess TCR repertoire of TRAF3-deficient versus wild-type Tregs

• IL-2 Signaling Analysis:

  • Research shows TRAF3 normally recruits the phosphatase PTPN2/TCPTP to the IL-2R to inhibit early signaling events

  • Compare IL-2-induced STAT5 phosphorylation between TRAF3-sufficient and TRAF3-deficient Tregs

  • Analyze downstream gene expression changes, particularly for IL-2-responsive genes

• Suppression Assays:

  • Assess the suppressive capacity of TRAF3-deficient Tregs using in vitro suppression assays

  • Compare the ability to suppress conventional T cell proliferation and cytokine production

  • Examine suppression of different T helper subsets (Th1, Th2, Th17)

• In Vivo Functional Studies:

  • Use adoptive transfer models to assess TRAF3-deficient Treg function in vivo

  • Examine their capacity to control autoimmunity or inflammatory disease models

  • Analyze their stability and persistence in different inflammatory environments

• GITR Expression Analysis:

  • Research indicates TRAF3-deficient T cells show increased GITR expression independent of the expanded Treg population

  • Compare GITR expression on Foxp3+ and Foxp3- T cell populations

  • Investigate the functional consequences of elevated GITR expression on T cell responses

How can researchers effectively study the interplay between TRAF3 and other TRAF family members in T cell biology?

TRAF family proteins often have overlapping and sometimes antagonistic functions in immune cells. To study the interplay between TRAF3 and other TRAF family members in T cells:

• Co-expression and Co-localization Studies:

  • Analyze the expression patterns of multiple TRAF proteins in different T cell subsets

  • Use immunofluorescence or proximity ligation assays to examine co-localization of TRAF3 with other TRAFs

  • Investigate how co-localization changes upon T cell activation or cytokine stimulation

• Combined Knockdown/Knockout Approaches:

  • Generate T cells deficient in TRAF3 alone, other TRAF proteins alone, or combinations

  • Compare phenotypes to identify synergistic, additive, or antagonistic relationships

  • Use inducible knockout systems to study temporal requirements for different TRAF proteins

• Competition Assays:

  • Examine whether different TRAF proteins compete for binding to shared receptors or adaptor proteins

  • Use overexpression of one TRAF to determine effects on the function of others

  • Employ domain-swapping experiments to identify regions mediating functional interactions

• Pathway-Specific Analysis:

  • Determine how different TRAF proteins affect common signaling pathways (NF-κB, MAPK, IRF)

  • Compare canonical versus non-canonical NF-κB regulation by different TRAFs

  • TRAF3 is known to act as a negative regulator of alternative NF-kappa-B pathway, which may contrast with other TRAF family functions

• Physiological Function Assessment:

  • Compare the effects of different TRAF deficiencies on T cell development, activation, and effector function

  • Examine impacts on specific T cell subsets (Th1, Th2, Th17, Treg)

  • Investigate T cell responses to different types of stimuli or pathogens

What methods can researchers use to investigate the differential roles of TRAF3 across different T cell subsets?

T cell subsets (CD4+ helper, CD8+ cytotoxic, regulatory, memory, etc.) have distinct functions and may utilize TRAF3 differently. To investigate these differential roles:

• Subset-Specific Conditional Knockout Models:

  • Generate conditional knockout models that delete TRAF3 specifically in CD4+ T cells, CD8+ T cells, or Tregs

  • Use Cre recombinase under control of subset-specific promoters (CD4-Cre, CD8-Cre, Foxp3-Cre)

  • Compare phenotypes to identify subset-specific requirements for TRAF3

• In Vitro Differentiation Assays:

  • Isolate naïve TRAF3-deficient T cells and differentiate them into various helper T cell subsets (Th1, Th2, Th17, Tfh)

  • Compare differentiation efficiency, stability, and functional capacity with wild-type cells

  • Analyze subset-specific signaling pathways and transcription factor activation

• Transcriptomic and Proteomic Profiling:

  • Perform RNA-seq and proteomics on different T cell subsets with and without TRAF3

  • Identify subset-specific gene expression patterns regulated by TRAF3

  • Use bioinformatic approaches to identify enriched pathways and networks

• Functional Assays Tailored to Each Subset:

  • For CD8+ T cells: cytotoxicity assays, granzyme/perforin expression

  • For Th1 cells: IFNγ production, T-bet expression

  • For Th2 cells: IL-4/IL-5/IL-13 production, GATA3 expression

  • For Th17 cells: IL-17 production, RORγt expression

  • For Tregs: suppression assays, Foxp3 stability

• In Vivo Infection and Disease Models:

  • Challenge mice with pathogens that elicit specific types of T cell responses

  • Viral infections for CD8+ and Th1 responses

  • Helminth infections for Th2 responses

  • Fungal infections for Th17 responses

  • Autoimmune models for Treg function

  • Compare the contribution of TRAF3 to protective immunity in each context

Studies have shown that TRAF3-deficient CD4+ T cells have altered cytokine production after TCR/CD28 stimulation, indicating subset-specific effects on helper T cell function .

How can innovative technologies be applied to better understand TRAF3's dynamic interactions in T cell signaling complexes?

Cutting-edge technologies offer new opportunities to study TRAF3's dynamic interactions and functions in T cells:

• Super-Resolution Microscopy:

  • Techniques like STORM, PALM, or STED microscopy can visualize TRAF3-containing complexes below the diffraction limit

  • Track the spatial organization of TRAF3 relative to TCR microclusters or cytokine receptor signaling domains

  • Examine reorganization of these complexes during T cell activation

• Single-Cell Analysis:

  • Single-cell RNA-seq to identify cell-to-cell variability in TRAF3-dependent gene expression

  • CyTOF (mass cytometry) to simultaneously measure multiple signaling nodes in TRAF3-sufficient versus TRAF3-deficient T cells

  • Single-cell proteomics to assess protein-level changes

• CRISPR Screens:

  • Conduct genome-wide or targeted CRISPR screens in T cells to identify genes that interact with TRAF3

  • Look for synthetic lethal or synthetic viable interactions

  • Identify modifiers of TRAF3-dependent phenotypes

• Intravital Microscopy:

  • Visualize TRAF3-deficient T cell behavior in vivo using two-photon microscopy

  • Examine interactions with antigen-presenting cells and migration within lymphoid tissues

  • Track activation dynamics in real-time within intact tissues

• Proximity Labeling Proteomics:

  • Use BioID or APEX2 proximity labeling fused to TRAF3 to identify proteins in close proximity under different conditions

  • This approach can capture transient interactions that might be missed by traditional co-immunoprecipitation

  • Compare interactomes in resting versus activated T cells or across different T cell subsets

• Optogenetic and Chemogenetic Tools:

  • Develop tools to acutely activate or inhibit TRAF3 function in specific subcellular locations

  • Study temporal aspects of TRAF3 signaling with precise control

  • Determine how the timing and location of TRAF3 activity affect downstream outcomes